Pharmacyclics, Inc. presented data on ibrutinib (IMBRUVICA), both as a single-agent and in combination with other treatments, during the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL.
IMBRUVICA is currently approved for the treatment of those suffering with chronic lymphocytic leukemia (CLL) which have already received at least one prior therapy; for all CLL patients with the a 17p deletion (part of chromosome 17 has been lost); and for all patients (including treatment-naive) with Waldenström’s macroglobulinemia.
This drug is an oral, first-in-class and once-daily therapy whose purpose is to inhibit a protein called Bruton’s tyrosine kinase (BTK) which stops the signaling pathway that allows malignant B cells to multiply and proliferate. IMBRUVICA is the only product with 3 Breakthrough Therapy Designations and is currently being assessed either alone or in combination with other treatments to address blood cancers. So far, over 6,100 patients have received treatment with IMBRUVICA in clinical trials conducted in 35 different countries.
“We look forward to sharing promising data at this year’s ASCO that examines the use of IMBRUVICA across a broad range of hematologic disease settings from our clinical studies. Addressing difficult-to-treat hematologic and solid malignancies remains a top priority for us and our development program is designed to help establish IMBRUVICA as a backbone of therapy across a broad range of histologies,” said the Head of Oncology at Pharmacyclics, Danelle James in a press release.
All abstracts presented can be consulted here; among them two specific studies addressing lymphoma can be found:
- A Randomized, Double-blind, Placebo-controlled, Phase III Study of rituximab with or without ibrutinib for Waldenstrom’s Macroglobulinemia. (Abstract TPS8599)
Poser Session: Lymphoma and Plasma Cell Disorders. Sunday, May 31 at 8:00 a.m. CDT in S Hall A.
Lead Author: Meletios A. Dimopoulos, M.D., National and Kapodistrian, University of Athens, Athens, Greece. - A Phase III Study of ibrutinib in Combination with Either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in Subjects with Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma. (Abstract TPS8601)
Poser Session: Lymphoma and Plasma Cell Disorders. Sunday, May 31 at 8:00 a.m. CDT in S Hall A.
Lead Author: Nathan Hale Fowler, M.D., The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
